TWD 40.9
(0.25%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 161.05 Million TWD | -20.0% |
2022 | 201.3 Million TWD | -16.57% |
2021 | 241.29 Million TWD | -6.36% |
2020 | 257.68 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 155.89 Million TWD | -3.2% |
2024 Q2 | 178.2 Million TWD | 14.31% |
2023 Q2 | 180.66 Million TWD | 1.13% |
2023 FY | 161.05 Million TWD | -20.0% |
2023 Q1 | 178.65 Million TWD | 0.0% |
2023 Q4 | 161.05 Million TWD | -12.42% |
2023 Q3 | 183.89 Million TWD | 1.78% |
2022 Q4 | - TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Allied Biotech Corporation | 910.11 Million TWD | 82.304% |
GeneFerm Biotechnology Co., Ltd. | 282.53 Million TWD | 42.998% |
Easywell Biomedicals, Inc. | 589.98 Million TWD | 72.702% |
TTY Biopharm Company Limited | 3.36 Billion TWD | 95.219% |
Synmosa Biopharma Corporation | 3.62 Billion TWD | 95.56% |
Orient EuroPharma Co., Ltd. | 6.64 Billion TWD | 97.578% |
Center Laboratories, Inc. | 6.78 Billion TWD | 97.627% |
Orient Pharma Co., Ltd. | 892.18 Million TWD | 81.949% |
InnoPharmax Inc. | 48.64 Million TWD | -231.049% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 320.99 Million TWD | 49.827% |
Excelsior Biopharma Inc. | 472.87 Million TWD | 65.942% |
DV Biomed Co., Ltd. | 765.87 Million TWD | 78.971% |
Foresee Pharmaceuticals Co., Ltd. | 616.93 Million TWD | 73.895% |
Handa Pharmaceuticals, Inc. | 280.88 Million TWD | 42.662% |
UniPharma Co., Ltd. | 37.4 Million TWD | -330.609% |
Anxo Pharmaceutical Co., Ltd. | 1.01 Billion TWD | 84.138% |
Alar Pharmaceuticals Inc. | 76.08 Million TWD | -111.663% |
Winston Medical Supply Co., Ltd. | 373.87 Million TWD | 56.924% |
Mercury Biopharmaceutical Corporation | 49.72 Million TWD | -223.911% |
Bioray Biotech Co., Ltd | 108.75 Million TWD | -48.091% |
TSH Biopharm Corporation Limited | 133.62 Million TWD | -20.524% |